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Kaposi sarcoma-associated herpesvirus (KSHV) is a human
-herpesvirus associatedwith several humanmalignancies. The
replication and transcription activator (RTA) is necessary and
sufficient for the switch from KSHV latency to lytic replication.
Toll-interleukin-1 receptor (TIR) domain-containing adaptor-
inducing -interferon (TRIF, also called TIR-domain-contain-
ing adaptor molecule-1 (TICAM-1)) is a signaling adaptor mol-
ecule that is critically involved in the Toll-like receptor 3
(TLR-3) and TLR-4 signaling pathways for type I interferon
(IFN) production, a key component of innate immunity against
microbial infection. In this report, we find a newmechanism by
which RTA blocks innate immunity by targeting cellular TRIF.
RTA specifically degrades TRIF by shortening the half-life
of TRIF protein. This RTA-mediated degradation is at least
partially mediated through the ubiquitin-proteasome pathway
because proteasome inhibitors as well as knockdown of cellular
ubiquitin expression alleviate the degradation. RTA may not
directly interact with TRIF and may activate TRIF degradation
indirectly through an unknownmediator(s). RTA targetsmulti-
ple regions of TRIF and may use its ubiquitin ligase domain
for the degradation. In addition, physiological levels of TRIF
protein are down-regulated duringKSHV lytic replicationwhen
RTA is expressed. Finally, RTA down-regulates double-
stranded RNA-initiated activation of TLR-3 pathway, in the
absence of degradationof IFN regulatory factor 7 (IRF-7). Taken
together, these data suggest that KSHV employs a novel mech-
anism to block the innate immunity by degrading TRIF protein.
This workmay contribute to our understandings on how KSHV
evades host immunity for its survival in vivo.
Kaposi sarcoma (KS)2-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), is a -herpesvirus. It
is believed to be the etiological agent of KS (1–3). KSHV is also
implicated in the pathogenesis of AIDS-associated primary
effusion lymphoma (also called body cavity-based lymphoma
(BCBL)) and a lymphoproliferative disorder known as multi-
centric Castleman disease (1, 4, 5).
As with other herpesviruses, KSHV goes through both
latency and lytic replication cycles. The expression of theKSHV
replication and transcription activator (RTA) is necessary and
sufficient for the switch from latency to lytic replication (4, 5).
RTA is an immediate early gene (6–8) and a sequence-specific
DNA-binding protein (7–13). RTA also interacts with other
factors tomodulate its transcription potential, such as with cel-
lular recombination signal sequence-binding protein-J (RBP-
J) (14–16).
RTA also modulates cellular activities through protein deg-
radation. The proteasome is amulticomponentmacromolecule
that is ubiquitous in eukaryotic cells and works as a cellular
machinery for degradation of proteins (17). The proteasome
degradation is usually ubiquitin-dependent involving ubiqui-
tin-activating enzyme E1, ubiquitin-conjugating enzyme E2,
and ubiquitin ligase E3 (17–19). RTA was first documented as
an E3 ligase for degradation of a cellular interferon regulatory
factor 7 (IRF-7) (20). Two more cellular proteins, K-RBP and
Hey, both are repressors of KSHV lytic replication and have
been identified as targets for degradation by RTAwith the same
pathway (21, 22).
The host innate immune system is essential for the initial
detection of invading viruses and subsequent activation of
adaptive immunity. Toll-like receptors (TLRs) are a family of
evolutionarily conserved receptors. TLRs are able to recognize
molecular patterns unique to pathogens and activate host
innate immunity against the pathogen (23, 24). One of the
major products from TLR activation is the production of type I
interferons (IFN). IFN is a key component to mount a proper
and robust immune response to a viral infection (25, 26).
Toll-IL-1 receptor (TIR) domain-containing adaptor-induc-
ing IFN- (TRIF), also called TIR domain-containing adaptor
molecule-1(TICAM-1), is an adaptor protein that is involved in
the signaling transduction during the activation of some TLRs,
leading to activation of NF-B and type I IFN (27–29). TLR-3
andTLR-4 seem to be dependent onTRIF for their downstream
cascades (27). Because TRIF is critically involved in TLR and
IFN production, it would be a natural strategy for viruses to
nullify TRIF for their own benefit. Vaccinia virus encodes two
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genes to differentially affect TRIF signaling (30, 31). Also, hep-
atitis C virus encodes a viral protease that cleaves TRIF (32).
Interestingly, the same viral protease also digests another gene
critically involved in IFN production (33).
IFN inhibits the KSHV replication in vitro (34–36). TLR-4
has been identified as an important molecule against KSHV
infection, and KSHV has developed a mechanism to rapid sup-
pression of TLR-4 expression (37). Also, murine -herpesvirus
68 (MHV68) is another herpesvirus with significant similarities
to KSHV. Activation of the TLR-3/TLR-4 pathway potently
inhibits the replication of MHV68 in vivo (38). At the same
time, KSHVs have a segment genomic DNA and protein prod-
uct (K8.1) that induce the production of IFNs (39, 40). KSHV
infects many cell types, including B lymphocytes and dendritic
cells (41–44). These cells express multiple TLRs, and dendritic
cells are potent IFN producers. Thus, a successful counterac-
tion of IFN activation may be a necessity for the survival of
KSHV in vivo.
KSHV encodes several genes to counteract the innate IFN
response. IRF-7 was first cloned in the context of Epstein-Barr
virus (EBV) latency (45) and is amaster gene for IFNproduction
(46). KSHV employs two mechanisms to nullify the function of
IRF-7; RTA mediates IRF-7 degradation in certain cell lines
(20), and ORF45 blocks the activation of IRF-7 to impair IFN
production (47). In addition, KSHV latency-associated nuclear
antigen (LANA) is able to block the activation of TBK1-medi-
ated activation of IRF-3 (48). KSHV encodes several viral
homologs of the IRF family of transcription factors (vIRF).
vIRF1, vIRF2, and vIRF3 are all able to block the production of
IFNs by functioning as dominant negative versions of cellular
IRFs (4, 5). Furthermore, KSHVORF10 is also able to block the
IFN signaling in KSHV-infected cells (49).
We have found a cell line in which IRF-7 could not be
degraded by RTA. However, IFN production was still inhibited
by RTA as reported previously (20). We have examined the
mechanism of this IRF-7 degradation-independent IFN inhibi-
tion and found that RTA degrades cellular TRIF protein, an
upstream adaptor protein involved in IFN production. This
report provides another mechanism by which KSHV nullifies
host innate immunity.
MATERIALS ANDMETHODS
Plasmids, Antibodies, and siRNA—Expression plasmids of
KSHV RTA and its mutant (RTA-K152E), EBV RTA, IRF-7,
pcDNA3.1-Myc-TRIF, and p56-luc (561-pGL3 luciferase
reporter construct) are as described previously (45, 50–54).
FLAG-TLR3 was a gift from Dr. Katherine Fitzgerald (55).
Ubiquitin-expressing plasmidwas a gift fromDr. Clinton Jones.
The mutagenesis to generate a mutant with deletion (amino
acids 318–514; TRIF-Del) was done by the use of PCR site-
directed mutagenesis kit (Invitrogen). The TRIF-N (amino
acids 1–514) and TRIF-C (amino acids 318–712) were done
with the use of PCR and cloned into 3-FLAG vector (Sigma).
The expression clones were all sequenced to verify the validity
of the clones. IRF-7 antibody was as described previously (45).
Tubulin (T6557) and FLAG antibody (F1804) were obtained
from Sigma. The antibodies for Myc (SC-40), IRF-1 (SC-497),
ubiquitin (SC-9133), and GAPDH (SC-47724) were from Santa
Cruz Biotechnology. TRIF antibody was from Cell Signaling
(catalog number 4596). siRNA to ubiquitin (siUb) was from
Santa Cruz Biotechnology (SC-29513), and siLuc was from
Thermo Scientific Dharmacon (D-002050-01-05).
Cell Culture—293T is a human fibroblast line. WT11(clone
9) is a TLR-3-expressing cell line (56) (gift fromDr. Ganes Sen).
Both cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Invitrogen) and 1% penicillin-streptomycin at
37 °C in 5% CO2 incubation. 400 g/ml G418 (Invitrogen) was
used to maintain the TLR-3 expression in WT11 cells. IB4 is a
KSHV-negative but EBV-positive cell line. BCBL1 is a KSHV-
positive primary effusion lymphoma line. These cells were
maintained in RPMI 1640 plus 10% FBS.
Transient Transfection, Drug Treatment, and Reporter
Assays—Effectene (Qiagen, Valencia, CA) was used for the
transfection of 293T or WT11-9 cell lines following the manu-
facturer’s recommendation. Proteasome inhibitors were as fol-
lows; lactacystin (80052-806) was fromVWR International and
used at the 1–10 M range, and MG132 (HPK-116) was pur-
chased from Assay Designs and used at 1–10 mM. For lactacys-
tin and MG132 treatment, cells were transfected, and medium
were removed 4–6 h after transfection. Fresh medium plus
proper concentrations of drugs were added. Cells were col-
lected 12–24h later. Poly(I-C) (double-strandedRNA)was pur-
chased from InvivoGen (tlrl-pic) and used at 10 g/ml. Lucif-
erase assays were performed using the assay kit from Promega
according to the manufacturer’s recommendation. -Galacto-
sidase assays were also performed for transfection efficiency.
Data were averaged from the triplicates.
Protein Stability Assays—Protein biosynthesis inhibitor,
cycloheximide, was purchased from Sigma (C4859) and used at
50–100 g/ml. Cells were transfected in 10-cm dishes, and
transfected cellswere split 4–6h after transfection into a 6-well
plate. On the next day, the cells were treated with cyclohexi-
mide for the indicated period, and cell lysates were made and
used for Western blot analysis.
Western Blot Analysis, RNA Extraction, and RNase Protec-
tion Assays (RPAs)—Standard Western blot analysis was per-
formed as described (57–59). Total RNAwas isolated from cells
using the RNeasy total RNA isolation kit (Qiagen) or TRIzol
extraction. RPA was performed with 10 g of total RNA using
the RNase protection assay kit II (Ambion, Houston, TX) at
55 °C. Sometimes, gradient temperatures were performed for
RPA when difficulties in RPA were encountered (60). The
GAPDH probe was from United States Biochemicals, Inc. The
probe for IFN- was a gift from Dr. Ganes Sen.
RESULTS
RTA Has an Additional Mechanism(s) to Block the IFN
Production—RTA has been shown to degrade cellular IRF-7 for
the blockage of IFN production (20).We have examined whether
RTA could degrade IRF-7 extensively and found that RTA was
unable to degrade IRF-7 in the cell line we used (293T) (Fig. 1A).
Because RTA blocks the production of IFN, this particular line is
therefore very useful to examine the role of IRF-7 in RTA-medi-
ated IFN production. IRF-7 was transfected with or without RTA,
and the cells were infected by Sendai virus. As shown in Fig. 1B,
KSHV RTADegrades TRIF
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endogenous IFN- production was greatly enhanced with IRF-7
expression. However, with the expression of KSHVRTA, the IFN
production was drastically reduced. The use of IFN- as amarker
for type I IFNproduction iswell established andappreciated in the
field. Because in our experimental system there was no apparent
IRF-7 degradation, even after the 6-h Sendai infection (Fig. 1A and
data not shown), the data suggest that KSHV RTA has an addi-
tional mechanism(s), other than degradation of IRF-7, for the
blockage of IFN production.
RTAReduces the Expression of TRIF Protein—Thedata in Fig.
1 suggested that RTA blocks transcription of IFN by targeting a
different protein involved in the innate immune response. We
thus examined several intermediates involved in IFN induction
for putative RTA targets, such as TRIF and RIG-I. 293T cells
were co-transfected with target gene and RTA expression plas-
mids, and 1 day later, the cell lysates were used to examine the
target gene expression. As shown in Fig. 2A, we found that TRIF
protein was reduced in the presence of RTA. This reduction
seems to be specific for KSHVRTA as EBVRTA (E-RTA) could
not reduce the expression of TRIF at the level expressed (Fig.
2B). EBV RTA and KSHV RTA have significant homologies,
and both viruses are -herpesvirus. We further examined
whether TRIF RNA levels were reduced when RTA was pres-
ent. The semiquantitative RT-PCR results indicated that TRIF
RNA was not obviously affected by RTA expression (data not
shown). Thus, the data suggest that RTAmay reduce TRIF pro-
tein expression to block IFN production.
RTA Modulates Protein Stability of TRIF—To test whether
RTA can alter TRIF protein stability, 293T cells were trans-
fected with TRIF, with or without RTA expression plasmid. 1
day later, cells were treated with cycloheximide for blockage of
protein synthesis. Cell lysates were made at various time points
after the drug treatment. As shown in Fig. 3, the TRIF protein
was quite stable at 7 h after treatment. However, the half-life of
TRIFwas reduced in the presence of RTA (Fig. 3B). The half-life
FIGURE 1. KSHV RTA blocks IFN production without IRF-7 degradation. A, RTA could not degrade IRF-7 in the 293T cells. IRF-7 expression plasmid (0.1g)
plus various amounts of RTA (0.2 g) were transfected into 293T cells in a 6-well plate. Total DNA for transfection was maintained the same with the use of
vectorDNA (pcDNA3). Lysateswereused forWesternblot analysis. The identity of proteins is as shown.B, RTA inhibits IFNproduction. IRF-7 expressionplasmid
(0.4 g) plus RTA (0.8g) were transfected into 293T cells in a 10-cm dish. 1 day later, cells were infected with Sendai virus (20 HA units/ml) for 6 h. Total RNA
was isolated, and RPA was performed with IFN- and GAPDH probes. The identity of RNA is as shown.
FIGURE 2. RTA reduces the expression of TRIF protein. A, RTA reduces TRIF
protein expression. 293T cells in 6-well plates were transfectedwith pcDNA3,
RTA (0.2g), and TRIF expression plasmid (0.1g) in various combinations as
shown on the top. Total DNA for transfection was maintained the same with
the use of vector DNA. The cell lysates were obtained 1 day later for Western
blot analysis. The identity of proteins is as shown. B, EBVRTA could not reduce
theexpressionof TRIF. 293T cellswere transfectedwithpcDNA3, RTA (0.2g),
E-RTA (0.2g), and TRIF expression plasmid (0.1g) in various combinations
as shown on the top. The cell lysates were obtained 1 day later. The mem-
brane was stripped and probed with another antibody. The images in the
same box indicate that they are derived from the samemembranes. The iden-
tity of proteins is as shown.
FIGURE 3.RTA alters the TRIF protein stability. 293T cells in a 10-cm dish
were transfected with TRIF (0.4g) (A) or TRIF plus RTA (0.8g) expression
plasmid (B). Total DNA for transfection was maintained the same with the
use of vector DNA. 6 h after transfection, cells were split into a 6-well plate.
Cycloheximide (100g/ml) was added after a 12-h incubation. Cell lysates
were made at various time intervals (in hours) as shown on the top, and
Western blot analysis was performed. The membrane was stripped and
probed with another antibody. The images in the same box indicate that
they are derived from the same membranes. The identity of proteins is as
shown.
KSHV RTADegrades TRIF
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of IRF-1 protein was also examined and was short as expected
(61). These results indicated that RTA reduced TRIF expres-
sion by altering protein stability.
An RTA Mutant Does Not Significantly Degrade the Expres-
sion of TRIF—To determine the region of RTA to promote the
degradation of TRIF, an RTA mutant (RTA-K152E) was used.
This mutant cannot induce the lytic replication of KSHV (50,
62) and fails to induce the degradation of K-RBP (22). As shown
in Fig. 4, the expression of TRIF was significantly reduced in
cells transfected with RTA; however, TRIF expression was par-
tially restored in the cells transfected with RTA-K152E. The
region (amino acids 118–207; Cys/His-rich domain) was
shown to be the putative domain as E3 ligase for IRF-7 and
other proteins (20, 22). The mutation (K152E) is within the
putative E3 ligase domain.
Multiple Regions of TRIF Are Targeted by RTA—To narrow
down the region(s) of TRIF for RTA-mediated degradation,
we have made several mutants as shown in Fig. 5A. The
TRIF-Del was made to remove the majority of the TIR
domain in TRIF. The TIR domain is a signature and used for
interaction with other proteins in TLR signaling. The dele-
tion mutant was transfected into 293T cells, and whether
RTA degrades the TRIF mutant was examined. As shown in
Fig. 5B, the TIR deletion TRIF was degraded by RTA. Next,
we made mutants containing the N or C terminus of TRIF
and the TIR domain. As shown in Fig. 5C, both TRIF-N and
TRIF-C were degraded in the presence of RTA. However, the
RTA-K152E mutant marginally degraded the proteins. The
RTA mutant also failed to degrade TRIF-Del (data not
shown). These data suggest that the RTA targets multiple
regions of TRIF for degradation.
RTA-mediated TRIF Degradation Is Mediated through
Proteasome—RTA has been shown to degrade several pro-
teins through the proteasome pathway (20, 22). To address
whether TRIF is also degraded through the proteasome, we
first used the proteasome inhibitor lactacystin. As shown in
Fig. 6A, lactacystin partially restored the expression of TRIF.
Another proteasome inhibitor, MG132, also partially
restored the TRIF protein expression (data not shown). Sec-
ond, we used siUb to knock down the endogenous ubiquitin.
As shown in Fig. 6B, siUb could partially restore the expres-
sion of TRIF, but siRNA for luciferase (siLuc) failed to do so.
The expression of ubiquitin was reduced in the presence of
siUb (Fig. 6B). Finally, whether ubiquitin could be added to
the TRIF molecule and increase its molecular weight was
examined. However, we could not detect any slowly migrat-
ing, high molecular weight TRIF present under our experi-
mental conditions (data not shown). It is possible that the
TRIF molecule might be too large, and the addition of lim-
ited ubiquitin molecule might not be as obvious for observa-
tion. We then tested whether the ubiquitination could be
observed in the TRIF-C as it is relatively small in molecular
weight. As shown in Fig. 6C, in the presence of RTA, a slowly
migrating, high molecular weight smear of TRIF-C, was ob-
served (Fig. 6C, lanes 1 and 2). Furthermore, increased levels
FIGURE 4.AnRTAmutant failed to reduce the protein expression of TRIF.
293T cells were transfected with vector pcDNA3, TRIF (0.1 g), RTA (0.2 g),
and RTA-K152E (0.1 g) expression plasmid in various combinations as
shown on the top. Total DNA for transfection was maintained the same with
the use of vector DNA. Cell lysates were made 1 day later, and Western blot
analysis was performed. The membrane was stripped and probed with
another antibody. The images in the same box indicate that they are derived
from the same membranes. The identity of proteins is as shown.
FIGURE 5. RTA targets multiple regions of TRIF for degradation. A, schematic diagram of TRIF mutant constructs. The numbers denote the amino acid
positions. The drawing is not to scale. B, TRIF-Del is degraded by RTA. 293T cells were transfectedwith vector pcDNA3, TRIF (0.1g), RTA (0.2g), and TRIF-Del
mutant (0.1g) expression plasmids in various combinations as shown on the top. Total DNA for transfection wasmaintained the samewith the use of vector
DNA. Cell lysatesweremade 1 day later, andWestern blot analysis was performed.Myc andGAPDH antibodieswere used. The identity of proteins is as shown.
C, both TRIF-N and TRIF-C are degraded by RTA. The two TRIFmutants, RTA, and RTA-K152E, were transfected into 293T cells with various combinations. FLAG,
Myc, GAPDH, and RTA antibodies were used for the Western blot. The images in the same box indicate that they are derived from the same membranes. The
identity of proteins is as shown.
KSHV RTADegrades TRIF
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of TRIF-C smears were observable when ubiquitin-express-
ing plasmid was co-transfected (lanes 3 and 4). The expres-
sion of ubiquitin was confirmed (data not shown). These
data provided evidence that RTA, at least partially, pro-
moted TRIF degradation via the proteasome pathway.
Expressions of RTA and TRIF Are Inversely Correlated at
Physiological Concentrations—Toexaminewhether RTAcould
degrade TRIF under physiological conditions, we induced the
lytic replication process in the KSHV latently infected BCBL
cell line. RTA is not expressed during the viral latency, but it is
a key mediator for the lytic replication. When KSHV-positive
BCBL1 cells were treated with sodium butyrate, the expression
of RTA was significantly increased (Fig. 7A). In addition, a
simultaneous down-regulation of endogenous TRIF expression
was observed. The same lysates were also used for the detection
of IRF-7, and the expression of IRF-7 was increased with the
sodium butyrate treatment, which is in a agreement with a pre-
vious report (63, 64). Furthermore, we testedwhether TRIFwas
degraded in KSHV-negative cell lines. IB4 is an EBV-trans-
formed cell linewith noKSHV.With the sodiumbutyrate treat-
ment, no degradation of TRIF was observed (Fig. 7B). The
induction of lytic replication by sodium butyrate is not 100%.
However, endogenous TRIF is apparently low as we had to con-
centrate the cell lysates for the detection of endogenous TRIF.
A slight induction of RTAmight be sufficient to degrade endog-
enous TRIF. All these results suggest that the reduction of TRIF
is specifically associated with the induction of KSHV RTA
under physiological conditions.
RTA Down-regulates the Activation of TLR-3 Pathway—Re-
cently, it has been shown that Sendai infection activates the
RIG-I pathway for IFN induction (65). Thus, it is possible that
the IFN blockage observed in Fig. 1 may not be related to TRIF
degradation completely. We thus examined whether RTA
could block a signaling pathway that absolutely requires TRIF.
TRIF is absolutely required for TLR-3 signaling (27). It is well
established that p56 is a good target and a marker of TLR-3
activation (56, 66, 67).We thus tested whether the activation of
p56 promoter by TLR-3 is affected by RTA expression. 293T
cells were transfected with RTA- and TLR-3-expressing plas-
mids, and transfected cells were treated with or without syn-
thetic double-strandedRNA (dsRNA). As shown in Fig. 8A, p56
promoter reporter was activated in response to TLR-3 and
dsRNA (columns 2 and 3).However, in the presence of RTA, the
activation was drastically reduced (columns 5 and 6). In addi-
tion to 293T cells, we also used the TLR-3-expressing cells
(WT11) (56). As shown in Fig. 8B, RTA reduced the dsRNA-
mediated activation of the p56 promoter reporter. All these
data suggested that RTA reduced TLR-3 signaling activities. Of
note, in our 293T cells, IRF-7 was not degraded by RTA (Fig.
1A). Therefore, the blockage of TLR-3 signaling may be related
to potential TRIF degradation.
DISCUSSION
IFN is important to control KSHV infection, and a suc-
cessful counteraction of IFN signaling may be a necessity for
the survival of KSHV in vivo. It is thus not surprising that
KSHV encodes several genes to counteract the innate IFN
system. IRF-7 is targeted by at least two KSHV proteins (20,
47). Latency-associated nuclear antigen is able to block the
FIGURE 6.RTAdegrades TRIF throughproteasomepathway.A, proteasome inhibitor alleviates TRIF degradation. 293T cells were transfectedwith pcDNA3,
RTA (0.2g), and TRIF expression plasmid (0.1g) in various combinations as shown on the top. Total DNA for transfectionwasmaintained the samewith the
use of vectorDNA. 6 h after transfection, cellswerewashed and treatedwith lactacystin. The cell lysateswere obtained 1day later forWesternblot analysis. The
identity of proteins is as shown. B, knockdown of ubiquitin alleviates TRIF degradation. 293T cells were transfected with pcDNA3, RTA (0.1 g), and TRIF (0.05
g) expression plasmids in various combinations as shown on the top. In addition, siUb or siLuc (5 pmol of each) were also transfected. Cell lysates weremade
1 day later, and Western blot analysis with TRIF antibody was performed. The membrane was stripped and probed with another antibody. The images in the
samebox indicate that they arederived from the samemembranes. The identity of proteins is as shown.C, ubiquitinwas added to TRIF-C. TRIF-Cor RTATRIF-C
were transfectedwith orwithoutHA-Ub expression plasmid. The cell lysateswere obtained 1day later forWestern blot analysis.More cell lysateswere used for
RTATRIF-C transfections. Two different exposures of the same membrane are shown. The identity of proteins is as shown.
FIGURE 7. TRIF is down-regulated during KSHV lytic replication. A, the
inverse correlation between the expression of RTA and TRIF. BCBL1 cells were
treated with sodium butyrate (NaButyrate) for 24 h. Cell lysates were made,
and the expression of endogenous proteins was analyzed by Western blot
analysis. Themembranewas strippedandprobedwith another antibody. The
same cell lysateswere used, and images in the samebox indicate that they are
derived from the same membranes. The identity of proteins is as shown.
B, sodium butyrate did not affect TRIF in KSHV-negative cell line (KSHV). IB4
cells (KSHV) were treatedwith sodiumbutyrate for 24 h, and the cell lysates
were made. The expression of TRIF was examined.
KSHV RTADegrades TRIF
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activation of IFN through IRF-3 (48). KSHV IRF homologs
(vIRF1, vIRF2, and vIRF3) are able to block the production of
IFNs by functioning as dominant negative versions of cellu-
lar IRFs. ORF10 blocks the IFN signaling in KSHV-infected
cells (49).
Protein degradation has been shown to be important for
antiviral responses (for a review, see Ref. 68). In this report,
we have shown that RTA could block the IFN production
without degradation of IRF-7 (Fig. 1). To address the possi-
ble mechanism behind this IRF-7 degradation-independent
phenomenon, we find that RTA targets TRIF for the block-
age of IFN production. First, we show that RTA reduces the
expression of TRIF, and the reduction is likely to be specific
to KSHV RTA as EBV RTA failed to reduce the expression of
TRIF (Fig. 2). Second, RTA affects the stability of TRIF as its
half-life is getting shorter in the presence of RTA (Fig. 3). In
addition, RT-PCR results indicated that TRIF RNA was not
affected by RTA (data not shown). Third, this RTA-mediated
degradation of TRIF seemed to be present under physiolog-
ical conditions as induction of lytic replication, and thus of
the RTA expression, reduces the expression of endogenous
TRIF protein (Fig. 7). Fourth and finally, the reduction of
TRIF may be responsible for the blockage of TLR-3-medi-
ated activation of p56 promoter in an IRF-7 degradation-
independent manner (Figs. 1 and 8).
This RTA-mediated degradation of TRIF is apparently
through the ubiquitin-mediated proteasome pathway. First,
RTA has been shown to be an E3 ligase for the degradation of
IRF-7, Hey1, and K-RBP. We have found that RTA-K152E
mutant lost some activity in degrading TRIF (Figs. 4 and 5). The
same mutant failed to degrade K-RBP (22). Also, the mutation
is located in the Cys/His-rich region (amino acids 118–207),
the putative E3 ligase domain (20, 22). Second, proteasome
inhibitors (lactacystin and MG132) partially restore the TRIF
protein expression (Fig. 6A and data not shown). Knockdown
of ubiquitin increases the TRIF expression (Fig. 6B). RTA
enhances high molecular weight smear formation in TRIF-C
protein, and the smear is likely to be ubiquitin as the overex-
pression of ubiquitin enhances the formation (Fig. 6C). All
these data suggest that RTA degrades TRIF, at least partially,
through ubiquitin-mediated proteasome pathway.
TRIF is a cytoplasmic protein andmainly localized to the cell
membrane (69), and KSHV RTA is a nuclear protein. We have
failed to show that RTA is directly interacting with TRIF in
co-immunoprecipitation assays (data not shown). In addition,
we have done the immunostaining of the two proteins together
in a cell and found that the two proteins were localized to the
cytoplasm and nucleus, respectively, and no obvious co-local-
ization was observed (data not shown). Thus, under our exper-
imental conditions, we failed to obtain convincing evidence
that the two proteins physically interact with each other
directly. However, we cannot exclude the possibility that the
two proteins may interact under some specific conditions/
times. Based on our data, we propose that the RTA-mediated
degradation ofTRIF is through an indirectmechanism inwhich
RTA activates an unknown cellular mediator(s) that facilitates
the degradation of TRIF.
Our results here suggest another novel pathway for KSHV to
evade the host innate immunity. Specifically, TLR-4 has been
identified as an important molecule against KSHV infection
recently, and KSHV has developed a mechanism for rapid sup-
pression of TLR-4 expression (37). TLR-4 activationwould lead
to activation of TRIF, which further leads to the induction of
type I IFNs. Therefore, this RTA-mediated degradation of TRIF
may be used byKSHV to escapeTLR-4-mediated innate immu-
nity. Finally, the degradation of TRIF was observed in KSHV-
infected cells under physiological concentrations (Fig. 7).
Therefore, this phenomenon might naturally occur in individ-
uals who have KSHV infection in vivo. The suppression of
TLR-4 expression as well as TRIF degradation collectively sug-
gest that the TLR-4 pathway is a critical one to control KSHV
infection, and the virus employs two mechanisms to block
TLR-4 activation.
It is known that KSHV infects B cells, where the majority of
TLRs are present (70). In addition, TRIF is an unexpectedly
multifunctional adaptor protein, mediating activation of sev-
eral transcription factors including NF-B, a key mediator for
pro-inflammatory cytokines (71). Additionally, TRIF may trig-
FIGURE 8. RTA blocks TLR-3 signaling. A, RTA blocks TLR-3 signaling in 293T cells. Various plasmids were transfected into 293T cells as shown on the top. 0.1
or 0.2gof TLR-3 (columns2,3,5, and6)wasused, respectively. RTA (0.2g)wasused for transfection. TotalDNA for transfectionwasmaintained the samewith
the use of vector DNA. After 4–6 h of transfection, the cellswere then treated () or not treated () with dsRNA (10g/ml). 1 day later, the cellswere collected,
and luciferase and-gal assayswere used for detection of reporter activation. The relative activation of p56 reporter (dsRNA/dsRNA) is as shown. Error bars
indicate S.D. B, RTA blocks TLR-3 signaling in TLR-expressing cells. Various plasmidswere transfected into TLR-3-expressing cells (WT11-9) as shownon the top.
0.2 or 0.4 g of RTA was used, respectively. The cells were then treated () or not treated () with dsRNA (10 g/ml). The relative activation of p56 reporter
(dsRNA/dsRNA) is shown. One representative result is shown. Error bars indicate S.D.
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ger apoptosis, and thus, degradation of TRIF may alleviate the
potential apoptosis process. It is tempting to speculate that
the RTA-mediated TRIF degradation may not be limited to the
blockage of IFNs, but also other cellular activities for the bene-
fits of KSHV in vivo.
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